Improved Drug Adherence Tied To Five Value-Based Insurance Design Features In Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Researchers found better adherence associated with reduced copays, targeting high-risk patients, wellness programs, mail order incentives and the lack of a concurrent disease management program.
You may also be interested in...
Driving Rx Adherence In Value-Based Insurance Design Needs More Than Lower Copays – Harvard Researcher
Value-based insurance design offers the promise of offering better quality care and helping to reduce costs, but getting there will require more than trying to influence behavior by reducing copayments, Harvard’s Choudhry said in a recent webinar.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.